PTC Therapeutics, Inc. Non Peo Neo Avg Total Comp Amt
PTC Therapeutics, Inc. (PTCT) reported Non Peo Neo Avg Total Comp Amt of $3.39 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-20.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-20
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $3.39M DEF 14A · filed 2026-04-20 |
| 2024-12-31 | $2.30M DEF 14A · filed 2026-04-20 |
| 2023-12-31 | $2.40M DEF 14A · filed 2026-04-20 |
| 2022-12-31 | $3.37M DEF 14A · filed 2026-04-20 |
| 2021-12-31 | $4.33M DEF 14A · filed 2026-04-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |